American consumer healthcare company Kenvue is implementing new ways to circumvent a potential tariff-related impact of £112.71 million ($150 million) on their business following the recent results of its Q1 2025.
The company, which recently became an independent shoot-off from pharmaceutical giant Johnson & Johnson in 2023, face challenges on how it can stay afloat amidst rising costs to production of its products such as Band-Aid, Tylenol, and Listerine, amongst others.
